25 October - 1 November 2019
These are links to news stories about multiple sclerosis from the last week that may be of interest to people affected by MS in the UK. The link beneath each item will take you to the original story.
Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.
To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts.
New recommendations for Lemtrada
Lemtrada should only used in highly active MS that hasn't been controlled by another disease modifying drug or where MS is worsening rapidly. These are the recommendations of a European Medicines Agency (EMA) committee which has been a safety review of Lemtrada since April. It is also recommended that the drug isn't used in people with heart or bleeding disorders or who have another autoimmune condition
MS Trust link: Lemtrada (alemtuzumab)
Stem cells treatment approved in Scotland
Haematopoietic stem cell transplantation (HSCT) can be considered an option for people in Scotland with relapsing remitting MS and who haven't done well on a disease modifying drug, according to an appraisal by the Scottish Health Technologies Group (SHTG). HSCT is not currently available for MS at any NHS hospitals in Scotland, though this ruling could allow referral to the two centres in England
Source: Herald Scotland
MS Trust link: Stem cell treatment
Causes and protection for cognitive symptoms
Factors that suggested poorer memory and thinking symptoms in someone with MS were older age and lower IQ, according to an Italian study. Older age at diagnosis and progressive MS were also associated with worse cognition while a higher level of activity when a child and HRT in women with MS tended to link with a better outcome
Source: MS News Today
MS Trust link: Thinking and memory problems
Infection risk is higher for people with MS
Some people with MS tend to have lower resistance to infections regardless of whether they take a disease modifying drug, according to Swiss/Greek research. About one in seven people had lower than normal levels of immunoglobulin G (IgG). People with secondary progressive MS had the lowest levels
Source: MS News Today
MS Trust link: MS research updates
Vumerity approved in the USA
The FDA, the US drug regulator, has approved Vumerity (diroximel fumarate) as a treatment for relapsing MS. The drug is similar to Tecfidera but with fewer gastrointestinal side effects. The approval process in Europe hasn't started yet
MS Trust link: Vumerity (diroximel fumarate)
Move it for MS Nick's story
7 Oct 2021 - 00:00
Nick, was diagnosed with relapsing remitting multiple sclerosis at the start of the first lockdown. In this story we talk to him about how he coped with his diagnosis and how running helps him with his MS.
David's diary - Inclusion and diversity, where are we now?
6 Oct 2021 - 00:00
Just over a year ago we published a diary entry about Inclusivity and Diversity at the MS Trust. In this piece we take a look at what's changed since then and what we still need to do.
Flu season 2021
4 Oct 2021 - 00:00
This year is likely to involve a bigger flu vaccination programme in the UK, including for people with multiple sclerosis (MS), due to the circulation of Covid-19 at the same time. Here we discuss who's eligible for a flu jab on the NHS and how to get one.
Sign up for updates from us
Keep up-to-date with the latest MS news, explore new research, read the stories of people living with MS, find out practical tips from MS experts, and discover exciting fundraising opportunities.